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Summary
Background Early in the pandemic it was suggested that pre-existing use of non-steroidal anti-inflammatory drugs 
(NSAIDs) could lead to increased disease severity in patients with COVID-19. NSAIDs are an important analgesic, 
particularly in those with rheumatological disease, and are widely available to the general public without prescription. 
Evidence from community studies, administrative data, and small studies of hospitalised patients suggest NSAIDs 
are not associated with poorer COVID-19 outcomes. We aimed to characterise the safety of NSAIDs and identify 
whether pre-existing NSAID use was associated with increased severity of COVID-19 disease.
Methods This prospective, multicentre cohort study included patients of any age admitted to hospital with a confirmed or 
highly suspected SARS-CoV-2 infection leading to COVID-19 between Jan 17 and Aug 10, 2020. The primary outcome 
was in-hospital mortality, and secondary outcomes were disease severity at presentation, admission to critical care, receipt 
of invasive ventilation, receipt of non-invasive ventilation, use of supplementary oxygen, and acute kidney injury. NSAID 
use was required to be within the 2 weeks before hospital admission. We used logistic regression to estimate the effects 
of NSAIDs and adjust for confounding variables. We used propensity score matching to further estimate effects of 
NSAIDS while accounting for covariate differences in populations.
Results Between Jan 17 and Aug 10, 2020, we enrolled 78 674 patients across 255 health-care facilities in England, 
Scotland, and Wales. 72 179 patients had death outcomes available for matching; 40 406 (56·2%) of 71 915 were men, 
31 509 (43·8%) were women. In this cohort, 4211 (5·8%) patients were recorded as taking systemic NSAIDs before 
admission to hospital. Following propensity score matching, balanced groups of NSAIDs users and NSAIDs non-users 
were obtained (4205 patients in each group). At hospital admission, we observed no significant differences in severity 
between exposure groups. After adjusting for explanatory variables, NSAID use was not associated with worse in-hospital 
mortality (matched OR 0·95, 95% CI 0·84–1·07; p=0·35), critical care admission (1·01, 0·87–1·17; p=0·89), requirement 
for invasive ventilation (0·96, 0·80–1·17; p=0·69), requirement for non-invasive ventilation (1·12, 0·96–1·32; p=0·14), 
requirement for oxygen (1·00, 0·89–1·12; p=0·97), or occurrence of acute kidney injury (1·08, 0·92–1·26; p=0·33).
Interpretation NSAID use is not associated with higher mortality or increased severity of COVID-19. Policy makers 
should consider reviewing issued advice around NSAID prescribing and COVID-19 severity.
Funding National Institute for Health Research and Medical Research Council.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction 
Non-steroidal anti-inflammatory drugs (NSAIDs) provide 
effective analgesia and are important in the treatment of 
inflammatory diseases. They form a part of the WHO pain 
ladder and have opioid-sparing properties, supported by 
data from randomised trials.1 In March, 2020, the French 
health ministry and media discussed unpublished data 
showing that use of NSAIDs could increase the severity of 
COVID-19.2,3 Debate ensued, with some arguing that 
NSAIDs should be avoided as a result of these findings.3–5 
This debate led to several regulatory authorities calling for 
urgent investigation of NSAIDs and COVID-19 severity.6
More recent studies have found no associations between 
NSAID use, admission to hospital, and worse outcomes 
for patients with COVID-19.7–13 These studies have been 
done in several different popula tions. In the community, 
administrative data have not shown an increased risk of 
hospitalisation for patients with COVID-19 taking 
NSAIDs.7,11,13 Data on patients admitted to hospital with 
COVID-19 are more scarce but suggest that patients 
taking NSAIDs do not have poorer outcomes compared 
with not taking NSAIDs.10–12 Studies that focus on cohorts 
of hospitalised patients with COVID-19 have included 
participants from single centres or included only small 
numbers of patients taking NSAIDs.
Studies of patients with non-SARS-CoV-2 respiratory 
infection have found associations between NSAID 
(including cyclooxygenase [COX]-2 inhibitors) use and 
increased rates of complications.14–19 These studies found 
that NSAID use was associated with higher rates of 
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myocardial infarction, pleural empyema, and longer 
length of hospital stay. However, outcomes used in such 
pneumonia studies, for example empyema, are less 
frequent in patients with SARS-CoV-2 infection. There are 
recognised safety concerns with the use of NSAIDs, 
including increased incidence of stroke, gastrointestinal 
bleeding, myocardial infarction, acute kidney injury, and 
bleeding,14–17,20 which are more common in older people.
By contrast, a randomised trial in the UK found that 
ibuprofen reduced the symptom severity of acute respira-
tory tract infection in patients in the community.21 In 
preclinical models, there is evidence that NSAIDs decrease 
pulmonary oedema, lessen endothelial leakiness, and 
reduce the severity of acute respiratory distress syndrome 
(ARDS), leading to the suggestion they might be useful in 
the treatment of COVID-19, with at least one clinical trial 
currently underway.22–24
We aimed to characterise the safety of NSAIDs and 
identify whether pre-existing NSAID use was associated 
with increased severity of COVID-19 disease.
Methods 
Study design and participants
The International Severe Acute Respiratory and Emerging 
Infection Consortium (ISARIC) Clinical Characterisation 
Protocol (CCP) for Severe Emerging Infection was 
developed in 2009 and activated in response to the 
SARS-CoV-2 pandemic on Jan 17, 2020. ISARIC-CCP-UK 
is an actively recruiting prospective cohort study across 
England, Scotland, and Wales. The protocol, revision 
history, case report forms, study information, and consent 
forms are available online. ISARIC CCP UK received 
ethical approval from the South Central—Oxford C 
Research Ethics Committee in England (13/SC/0149) and 
by the Scotland A Research Ethics Committee (20/SS/0028). 
As required, patients gave written informed consent. The 
study is reported in line with the STROBE guidelines.25
Patients of any age admitted to hospital with a 
confirmed or highly suspected SARS-CoV-2 infection 
leading to COVID-19 between Jan 17 and Aug 10, 2020, 
were eligible for inclusion in the study. Confirmation of 
SARS-CoV-2 infection was by reverse transcription-PCR, 
which was the only testing method available in the UK 
during the reported study period. Highly suspected cases 
were eligible for inclusion, given that SARS-CoV-2 was an 
emergent pathogen at time of protocol activation. We 
excluded patients who did not have death or discharge 
outcomes available.
Procedures
Data were collected by clinical research staff using a 
standardised case report form and entered into a Research 
Electronic Data Capture secure online database.26 Data 
were captured across multiple timepoints, including 
admission, hospital stay (days 1, 3, 6, and 9), and discharge. 
Characteristics captured included age, sex, asthma, chronic 
cardiac disease, chronic haematological disease, chronic 
kidney disease, chronic neurological disease, chronic non-
asthmatic pulmonary disease, HIV/AIDs, malignancy, 
liver disease, obesity, rheumatological dis order, and 
smoking history. Physiological parameters at admission 
were captured, including components of the National 
Early Warning Score 2 (NEWS2) and the quick Sequential 
Organ Failure Assessment (qSOFA).
Current medication or medication taken within the past 
2 weeks was recorded on hospital admission. The NSAID 
group was defined as patients taking generic or branded 
NSAIDs available within the UK, determined using the 
NHS Technology Reference data update distribution 
service, which were mapped to entered drug names within 
Research in context
Evidence before this study
There have been anecdotal reports that use of non-steroidal 
anti-inflammatory drugs (NSAIDs) is linked to COVID-19 
severity and poor outcomes. NSAIDs are an important analgesic 
class, used in the management of acute pain and 
rheumatological diseases. We searched PubMed from inception 
to Jan 12, 2021, using the terms “NSAIDs” and “COVID-19”, 
with no language restrictions. Several studies, in various 
populations, have identified that patients taking NSAIDs who 
contract SARS-CoV-2 infection are not at higher risk of 
admission to hospital or death. However, the populations 
included in these studies are frequently small, based on routine 
administrative data, or are drawn from community populations 
and hence have relatively low rates of SARS-CoV-2 infection.
Added value of this study
This prospective, multicentre study at 255 UK healthcare 
facilities found that in patients who were admitted to hospital 
with COVID-19, those taking NSAIDs before admission had the 
same outcomes as those who did not. We did not find any 
differences in mortality or disease severity, or in secondary 
outcomes including admission to critical care, use of ventilation, 
use of oxygen, or presence of acute kidney injury.
Implications of all the available evidence
Those taking NSAIDs do not appear to have poorer COVID-19 
outcomes. To our knowledge, our prospective study includes 
the largest number of patients admitted to hospital with 
COVID-19 to date, and adds to the literature on the safety of 
NSAIDs and in-hospital outcomes. NSAIDs do not appear to 
increase the risk of worse in-hospital outcomes. NSAIDs are an 
important analgesic modality and have a vital opioid-sparing 
role in pain management. Patients and clinicians should be 
reassured by these findings that NSAIDs are safe in the context 
of the pandemic.
For the study protocol, revision 
history, case report and 
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the study database. We defined exposure to NSAIDs as 
patients taking non-selective COX inhibitors or COX-2 
specific inhibitors. Topical NSAID preparations were 
excluded. Aspirin was not considered an NSAID for the 
purposes of this analysis, as aspirin is frequently used for 
the treatment and prevention of conditions which are 
different to those for which NSAIDs are indicated.
Outcomes 
The primary outcome was in-hospital mortality (including 
palliative discharge). Secondary outcomes were admission 
to critical care (level 3 intensive care unit or level 2 high 
dependency unit), use of invasive mechanical ventilation, 
use of non-invasive ventilation, use of supplementary 
oxygen, and occurrence of acute kidney injury. Acute 
kidney injury was defined according to the Kidney 
Disease: Improving Global Outcomes guidelines.27 We 
followed up patients for the duration of their hospital 
admission. Patients who were admitted after Aug 3, 2020, 
were excluded to avoid bias from patients with a long 
hospital stay or who had not had adequate time to accrue 
secondary outcomes.
Statistical analysis 
Categorical data are presented as frequencies and per cent-
ages. Normally distributed variables are summarised as 
mean (SD) and non-normally distributed variables as 
median (IQR). χ² test was used to compare categorical 
data, except where expected cell counts were five or fewer, 
in which case Fisher’s exact test was used. Contin uous 
variables were compared using Welch’s t-test or the 
Kruskall-Wallis test, depending on the distribution of data.
We used propensity score matching to estimate the 
treatment effect of NSAIDs while accounting for covariate 
imbalance, using a multistep approach. First, multiple 
imputation by chained equations was done using available 
explanatory variables (age, sex, diabetes [type 1 or type 2], 
chronic cardiac disease, chronic renal disease, obesity, 
chronic pulmonary disease, ethnicity, dementia, and 
rheumatological disease) and outcomes (five imputed 
datasets with five iterations per dataset; distributions 
checked graphically, and convergence confirmed). Second, 
logistic regression was used to determine the log odds of 
NSAID use (propensity scores) using the variables stated 
above. For logistic regression models, patient-level explan-
a tory variables were entered as fixed effects and in 
unmatched models, hospital was used as a random effect. 
We did not use random effects for matched models to 
ensure we could match on clinical characteristics, rather 
than restrict matches to within each centre. Following this, 
propensity score matching was done within each imputed 
dataset, and patients taking NSAIDs were matched (1:1) 
with their nearest neighbour not taking NSAIDs.28 Balance 
was determined using standardised mean differences. 
Fourth, effects estimates were determined, and results 
were pooled using Rubin’s rules.29 Effect estimates are 
presented as odds ratios (ORs) for binary outcome data, 
with corresponding 95% CIs. Imputed and matched data 
are presented as pooled models.
For unmatched models, clinically plausible variables 
associated with NSAID use and clinical outcomes were 
incorporated into the modelling approach. These variables 
included age, sex, and presence of chronic cardiac disease, 
chronic pulmonary disease, diabetes, obesity, chronic renal 
disease, rheumatological disease, and dementia. First 
order interactions were checked before final model 
selection, which was guided by minimisation of the Akaike 
Information Criterion. p<0·05 was considered to indicate 
a statistically significant difference.
We did four separate sensitivity analyses. First, we 
included patients taking non-ibuprofen NSAIDs only, as 
these usually require a prescription in the UK and are 
more likely to be taken for longer periods than ibuprofen. 
Next, we did an analysis including patients who were 
admitted at least 7 days after symptom onset to investigate 
whether NSAID use had any effect in those without 
nosocomial infection. We then did an analysis confined to 
patients with rheumatic disease, as this group are likely to 
be on long-term NSAID treatment compared with 
individuals who might be taking NSAIDs for short-term 
analgesia. Finally, to ensure the secondary outcomes were 
robust and to establish whether death was likely to compete 
with these outcomes, we did three sensitivity analyses to 
see if death altered the direction or magnitude of the effect 
size. For the first sensitivity analysis we excluded those 
who died. For the second sensitivity analysis we used 
deterioration (death or requirement for critical care) as the 
outcome. Lastly, for the third sensitivity analysis, we looked 
at mortality by NSAID use only in those not admitted to 
critical care.
Data were analysed using R version 3.6.3, using the 
tidyverse, finalfit, mice, MatchThem, cobalt, and matchit 
packages.
Role of the funding source 
The funders of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report.
Figure 1: Study profile
4211 using NSAIDs 
72 179 patients with mortality outcomes 
available for matching
78 674 patients included up to Aug 10, 2020 
67 968 not using NSAIDs
4205 using NSAIDs with variables 
available for matching for 
primary outcome 
(mortality)
4205 not using NSAIDs matched 
1:1 for primary outcome 
(mortality)
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Results 
Between Jan 17 and Aug 10, 2020, we enrolled 
78 674 patients across 255 health-care facilities in 
England, Scotland, and Wales (figure 1), representing 
around 60% of the total number of people admitted to 
hospital with COVID-19 over that time period. 
72 179 patients had death outcomes available for 
matching. We observed no large differences in distri-
bution of explanatory variables by missing mortality 
outcome (appendix p 1). In this cohort, 4211 (5·8%) 
patients were recorded as taking systemic NSAIDs 
before admission to hospital. In the unmatched data, 
patients who received NSAIDs were more likely to be 
female, and significantly more likely to have pre-existing 
rheumatological disease (table 1; appendix p 2). 
Propensity score matching produced balanced, well-
matched treatment groups for each set of imputed and 
pooled models (appendix pp 3–8, 13).
1279 (30·4%) of 4211 patients in the NSAID group died 
versus 21 256 (31·3%) of 67 698 patients in in the no 
NSAIDs group (table 2; appendix p 14). In the unmatched 
cohort, in-hospital mortality was no different between 
NSAID users and non-users (table 2). After matching, 
NSAID use was not associated with worse in-hospital 
mortality (matched OR 0·95, 95% CI 0·84–1·07; p=0·35; 
table 3).
In a sensitivity analysis of patients admitted to hospital 
at least 7 days after symptom onset (19 734 [27·3%] of 
72 179 patients) who were taking NSAIDs matched to 
patients not taking NSAIDs who presented during the 






Age at admission, years (n=71 987) 70·2 (18·4) 70·1 (18.7) 0·765*
Sex (n=71 915) ·· ·· 0·0008
Male 38 151 (56·1%) 2255 (53·6%) ··
Female 29 564 (43·5%) 1945 (46·2%) ··
Missing 253 (0·4%) 11 (0·3%) ··
Ethnicity (n=64 123) ·· ·· 0·116
Asian 3708 (5·5%) 230 (5·5%) ··
Black 2358 (3·5%) 118 (2·8%) ··
White 50 124 (73·7%) 3109 (73·8%) ··
Other 4201 (6·2%) 275 (6·5%) ··
Missing 7577 (11·1%) 479 (11·4%) ··
Smoking status (n=43 585) ·· ·· 0·0001
Current smoker 3588 (5·3%) 228 (5·4%) ··
Never smoked 22 896 (33·7%) 1394 (33·1%) ··
Former smoker 14 428 (21·2%) 1051 (25·0%) ··
Missing 27 056 (39·8%) 1538 (36·5%) ··
Chronic cardiac disease (n=67 454) ·· ·· <0·0001
No 42 831 (63·0%) 2557 (60·7%) ··
Yes 20 588 (30·3%) 1478 (35·1%) ··
Missing 4549 (6·7%) 176 (4·2%) ··
Chronic kidney disease (n=66 964) ·· ·· 0·042
No 51 800 (76·2%) 3237 (76·9%) ··
Yes 11 167 (16·4%) 760 (18·0%) ··
Missing 5001 (7·4%) 214 (5·1%) ··
Chronic pulmonary disease (not asthma; 
n=67 171)
·· ·· 0·0030
No 51 933 (76·4%) 3219 (76·4%) ··
Yes 11 232 (16·5%) 787 (18·7%) ··
Missing 4803 (7·1%) 205 (4·9%) ··
Obesity (as defined by clinical staff; n=60 199) ·· ·· <0·0001
No 49 993 (73·6%) 3039 (72·2%) ··
Yes 6590 (9·7%) 577 (13·7%) ··
Missing 11 385 (16·8%) 595 (14·1%) ··
Diabetes (n=65 135) ·· ·· 0·189
No diabetes 46 728 (68·8%) 2881 (68·4%)
Diabetes with complications 4484 (6·6%) 299 (7·1%) ··
Diabetes without complications 10 150 (14·9%) 593 (14·1%) ··
Missing 6606 (9·7%) 438 (10·4%) ··
Rheumatological disorder (n=66 228) ·· ·· <0·0001
No 55 469 (81·6%) 3145 (74·7%) ··
Yes 6809 (10·0%) 805 (19·1%) ··
Missing 5690 (8·4%) 261 (6·2%) ··
Dementia (n=66 788) ·· ·· 0·0003
No 51 980 (76·5%) 3368 (80·0%) ··
Yes 10 845 (16·0%) 595 (14·1%) ··
Missing 5143 (7·6%) 248 (5·9%) ··
Data are mean (SD) or n (%). NSAID=Non-steroidal anti-inflammatory drug. *Welch’s two-sample t-test used.






Mortality (n=72 179) ·· ·· 0·227
No 46 712 (68·7%) 2932 (69·6%) ··
Yes 21 256 (31·3%) 1279 (30·4%) ··
Critical care admission 
(n=70 955)
·· ·· 0·467
No 57507 (86.1%) 3599 (85.7%) ··




No 60 254 (91·5%) 3821 (91·9%) ··




No 55 809 (85·0%) 3452 (83·3%) ··




No 22 826 (34·6%) 1420 (34·2%) ··
Yes 43 147 (65·4%) 2731 (65·8%) ··
Acute kidney injury 
(n=68 228)
·· ·· 0·034
No 48 258 (75·1%) 2945 (73·6) ··
Yes 15 970 (24·9%) 1055 (26·4) ··
NSAID=Non-steroidal anti-inflammatory drug.
Table 2: Unmatched outcomes by NSAID use
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(matched OR 1·11, 95% CI 0·88–1·39; p=0·37). In 
patients with rheuma tological disease (7614 [10·5%] 
of 72 179), use of NSAIDs was not associated with 
increased mortality (matched OR 0·90, 0·68–1·19; 
p=0·44).
In the unmatched cohort, NSAID users were more 
likely to require non-invasive ventilation and sustain 
acute kidney injury (table 2). After matching, those taking 
NSAIDs were no more likely to require critical care 
admission (1·01, 0·87–1·17; p=0·89), invasive ventilation 
(0·96, 0·80–1·17; p=0·69), non-invasive ventilation (1·12, 
0·96–1·32; p=0·14), or supplementary oxygen (1·00, 
0·89–1·12; p=0·97), or to sustain acute kidney injury 
(1·08, 0·92–1·26; p=0·33), compared with those not 
taking NSAIDs (table 3; appendix p 14). In addition, on 
admission to hospital, matched patients on NSAIDs had 
similar qSOFA and NEWS2 scores to those who did not 
receive NSAIDs (table 3; figure 2). When we did a 
sensitivity analysis, excluding those who died, our 
findings did not change, and we did not observe an 
increase or decrease in associations between NSAIDs and 
any of the secondary outcomes (appendix p 9). We did a 
further two sensitivity analyses to ensure the secondary 
outcomes were robust. First, we combined death and 
critical care outcomes. Second, we looked at mortality in 
the population who did not require critical care. These 
analyses showed no association between NSAIDs and the 
chances of death or admission to critical care when these 
outcomes were combined (OR 0·94, 95% CI 0·83–1·06; 
p=0·28), nor any association with death in patients who 
were not admitted to critical care (0·92, 0·82–1·03; 
p=0·16).
The most common NSAID used was ibuprofen, 
followed by other NSAIDs—eg, diclofenac, ketorolac, 
naproxen, oxicams—and COX-2 inhibitors. We found no 
significant differences in mortality by type of NSAID 
(appendix p 10). We created matched groups to compare 
ibuprofen with no NSAID use, and ibuprofen with other 
NSAIDs, as a sensitivity analysis to explore whether 
NSAIDs associated with longer-term use had a different 
safety profile compared with ibuprofen. Use of ibuprofen 
was not significantly associated with increased mortality 
compared with those not taking NSAIDs (matched 
OR 0·90, 95% CI 0·71–1·13; p=0·36; appendix p 11) or 
any other NSAID (matched OR 0·82, 0·66–1·03; 
p=0·082; appendix p 12).
Discussion 
In this study, patients admitted to hospital with 
COVID-19 who were taking NSAIDs did not have more 
severe disease than did patients who were not taking 
NSAIDs. Mortality, critical care admission, respiratory 
support, and acute kidney injury were also not 
significantly different across matched NSAID treatment 
groups. We found no evidence of harm caused by NSAID 
use in patients admitted to hospital with severe 
COVID-19.
Early on in the COVID-19 pandemic, questions were 
raised concerning the safety of NSAIDs in patients with 
COVID-19, with suggestions that these drugs were 
leading to more severe disease in a some patients.2,30,31 
Our data show that patients taking NSAIDs did not have 
more severe symptoms or poorer outcomes than those 
not taking NSAIDs. These data support community 
studies showing that NSAID users did not have higher 
rates of hospitalisation with COVID-19 and smaller 
studies of in-hospital outcomes, which found NSAID use 
was not associated with poorer outcomes. A propensity 
matched data linkage study of patients with osteoarthritis 
taking NSAIDs in the community setting found no 
difference in the risk of developing COVID-19 or dying 
from the disease.13 Compared with our data and previous 
studies our consortium has published, this data linkage 
study13 did not find any differences in risk factors for 
mortality after COVID-19, which is probably due to the 
very small numbers of patients with COVID-19 in the 
study. To our knowledge, our study is the largest study of 
in-hospital outcomes of patients with COVID-19 to date. 
Considering all the evidence, if there was an extreme 
effect of NSAIDs on COVID-19 outcomes or severity, this 
would have been observed in one or more of the studies 
that have been done, including the present study.
Effect estimate p value
In-hospital mortality
No NSAIDs 1 (ref) ··
NSAIDs (n=4205) 0·95 (0·84 to 1·07) 0·35
Secondary outcomes
No NSAIDs 1 (ref) ··
NSAIDs
Critical care admission (n=4198) 1·01 (0·87 to 1·17) 0·89
Invasive ventilation (n=4156) 0·96 (0·80 to 1·17) 0·69
Non-invasive ventilation 
(n=4142)
1·12 (0·96 to 1·32) 0·14
Oxygen (n=4151) 1·00 (0·89 to 1·12) 0·97
Acute kidney injury (n=4000) 1·08 (0·92 to 1·26) 0·33
Severity on admission
Physiological scores
qSOFA score (n=3793) –0·02 (–0·06 to 0·02) 0·42
NEWS2 (n=3721) –0·08 (–0·30 to 0·14) 0·46
Physiological parameters
Heart rate (n=4102) –0·40 (–1·39 to 0·59) 0·43
Respiratory rate (n=4096) –0·17 (–0·66 to 0·32) 0·48
Saturation of peripheral oxygen 
(n=4076)
–0·00 (–0·27 to 0·26) 0·98
Systolic blood pressure (n=4085) 1·09 (–0·07 to 2·25) 0·066
Diastolic blood pressure (n=4071) –0·21 (–0·93 to 0·51) 0·56
Effect estimates are either matched odds ratio (95% CI) or mean difference (95% 
CI). NSAID=non-steroidal anti-inflammatory drug. NEWS2=National Early 
Warning Score 2. qSOFA=quick Sequential Organ Failure Assessment. 
Table 3: Outcomes after propensity score matching between those using 
NSAIDs before admission and those not using NSAIDs
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To our knowledge, worldwide, this is the largest 
prospective study of patients admitted to hospital with 
COVID-19. We were able to collect real-time data on 
patients to study their outcomes and collect detailed 
comorbidity data. Clinical research staff collected data on 
medications that patients had been prescribed or were 
currently taking, or had been taking within the past 
14 days. These data would otherwise be challenging to 
obtain from routine sources of health-care data. Although 
we have only captured data on patients admitted to 
hospital with COVID-19 that are available within the 
ISARIC CCP, this represents around 60% of all patients 
hospitalised with COVID-19 in the UK during the period 
of the study. We did not capture data for patients who had 
the disease in the community and did not require 
hospital admission, or who died in the community 
without hospital admission. Despite this, we expect that 
most patients who had severe COVID-19 would be 
admitted to hospital and thus captured in our dataset. A 
further potential limitation of our study is the absence of 
information on the indication for NSAIDs and duration 
of use. These missing data make it difficult to know 
whether individuals were taking NSAIDs for long-term 
conditions, or symptomatic relief for COVID-19 
symptoms. Similarly, it is unclear whether patients 
continued taking NSAIDs during their inpatient 
admission. Therefore, we are unable to make any 
recommendations on whether NSAIDs should be 
continued after admission to hospital. To address this, 
we did a sensitivity analysis comparing use of ibuprofen 
to no NSAIDs or use of other non-ibuprofen NSAIDs, as 
ibuprofen use is most likely to be short-term. We 
observed no increase in poorer outcomes in those who 
used ibuprofen compared with those who did not use 
NSAIDs. Similarly, older patients, who are at greatest 
risk of adverse outcomes from COVID-19, might be less 
likely to be taking NSAIDs compared with other, more 
healthy and fit populations, as older patients with greater 
numbers of comorbidities are less likely to be prescribed 
NSAIDs because of their side-effect profile; therefore, 
our matching might not have incorporated this patient 
group fully. However, as older patients are less likely to 
be taking NSAIDs and the safety debate concerns 
younger populations, this is unlikely affect our results 
and their relevance to clinical practice.
There are several other important limitations to our 
study that must be considered. First, the most used 
NSAID was ibuprofen, which might not be generalisable 
to every country. Different NSAIDs are known to have 
different side-effect profiles; therefore, clinical trials of a 
specific compound might not be generalisable to an 
entire drug class.32 Additionally, our data did not contain 
information on drug dosages or adherence, so we were 
unable to model dose–response data. Second, although 
our study captured data on most patients hospitalised 
with COVID-19 in the UK during the period it was done, 
a few centres did not participate. However, our data is 
concordant with other datasets that focused on smaller 
populations within our study, such as data from the 
Intensive Care National Audit and Research Centre.33 
Therefore, we consider our data to be meaningful and 
useful to help answer important clinical questions in 
patients with COVID-19. Another limitation is that to 
obtain the best possible matches for patients receiving 
NSAIDs, we did not include the date of admission as a 
matching variable. Mortality for patients admitted to 
hospital over the course of the pandemic has decreased, 
Figure 2: Physiological parameters on admission to hospital in NSAID users and those not taking NSAIDs
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but this is unlikely to have affected our conclusions given 
that the time period we conducted our study during was 
limited largely to the first UK wave of infection. Finally, 
our data lack a non-SARS-CoV-2 comparator group to 
provide a temporal comparison with other critical illness 
or respiratory conditions. Future research could include 
a comparator group to investigate if NSAIDs modify or 
moderate outcomes of interest in patients with COVID-19 
compared with other illnesses.
Although use of NSAIDs could, in theory, be beneficial 
in patients with COVID-19, we did not identify any 
evidence to support this. Clinical studies have suggested 
that release of proinflammatory mediators in COVID-19—
including interleukin (IL)-1β, IL-6, and CCL2—is asso-
ciated with more severe disease.34,35 Preclinical studies in 
non-COVID-19 models have found that release of these 
cytokines can be inhibited by treatment with NSAIDs, 
leading to discussion around whether NSAIDs might be 
useful as a therapy for COVID-19.23,36,37 In these studies, 
NSAIDs have been shown to suppress IL-6 production 
and expression through various mechanisms, including 
suppression of prostaglandin E2, which upregulates 
production of IL-6 and IL-8.36,37 Studies in bronchial 
epithelium have found that treatment with NSAIDs 
reduces expression of inflammatory mediators, including 
IL-6.36 A clinical trial of dexamethasone, which also has 
been shown to modulate inflammation,38 albeit probably 
through a separate mechanism, has been shown to 
reduce mortality in patients with COVID-19. Other 
immunomodulatory therapies are being trialled, 
including the IL-6 inhibitor tocilizumab. Results from the 
REMAP-CAP39 and RECOVERY40 trials  showed that 
tocilizumab reduced the requirement for organ support 
and improved survival in patients with COVID-19, with 
further trials underway.41,42 In addition to these trials, a 
randomised trial of ibuprofen in patients with COVID-19 
is also underway.23
For clinicians and patients, our findings should provide 
reassurance that NSAIDs can be used as indicated in the 
community without increasing the severity of COVID-19. 
Our study did not capture whether NSAIDs were 
continued in hospital, so we cannot make any recommen-
dations on whether these should be withheld or continued 
after hospital admission. There are important groups of 
patients who rely on NSAIDs for pain relief, including 
those with inflammatory joint diseases, bone pain, gout, 
postoperative pain, and menstrual pain, who would 
otherwise have few non-opioid options for pain relief. 
Taken together, clinicians should continue to prescribe and 
manage NSAIDs in the same way as before the COVID-19 
pandemic began.
Future research in this area should focus on whether 
NSAIDs sufficiently modulate inflammation in 
COVID-19, by using both basic science and clinical 
approaches using appropriate outcomes that are directly 
measured. If benefit or harm is identified, finding the 
cellular mechanisms responsible for these effects will be 
important to inform the biological understanding of 
COVID-19. Finally, including groups that compare 
NSAIDs with alternative analgesics should be considered 
to provide evidence for clinicians and patients on the risks 
associated with alternative medications. In conclusion, 
policy makers should consider reviewing issued advice 
around NSAID prescribing and COVID-19 severity. 
NSAID use is not associated with poorer outcomes in 
patients admitted to hospital with COVID-19.
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